Anyone comparing options here runs into the same obstacle within about ten minutes: the question of at-home ketamine: what the fda said and why looks straightforward until you try to answer it with real numbers. This guide sets out what is actually established, what varies between providers, and what to establish before committing to anything, written as continuous explanation rather than a checklist, because the reasoning is what transfers to your own situation.
A separate line of research has examined rapid reduction in suicidal ideation specifically, which is a distinct question from sustained treatment of depression. Nothing about the United States changes that. Read against the the United States market, the gap between anaesthetic and psychiatric dosing is large enough that describing them as the same treatment obscures more than it explains. A clinic that agrees to treat anyone who asks, without reference to what has already been tried, has replaced clinical judgement with a booking system. The practical difference is that esketamine is approved and more often insurable but less flexible, while intravenous ketamine is off-label, usually self-funded and more adjustable. The the United States listings on this page are organised so that this is checkable rather than assumed. An anaesthesiologist and a psychiatrist offering the same infusion are often running quite different programmes around it.
Side effects during a session are common, usually transient, and worth knowing about in advance rather than discovering in the chair. Dissociation is the one people ask about most: a sense of distance from the body, altered perception of time, sometimes visual distortion. For most people it peaks partway through the infusion and resolves within twenty to thirty minutes of the drip finishing. Nausea is frequent enough that many clinics give an antiemetic pre-emptively. Blood pressure and heart rate typically rise modestly during administration, which is the reason continuous monitoring is standard and the reason uncontrolled hypertension is treated as a serious caution. Headache, dizziness and a period of grogginess afterwards are ordinary. Driving is prohibited for the rest of the day without exception.
How the pieces fit together in practice
A history of psychosis or a bipolar diagnosis changes the risk calculation substantially, which is why a thorough intake asks about family psychiatric history and not only personal history. Acting on a different receptor system explains both the speed of onset and why the treatment sometimes helps people whom other antidepressants have not. In the United States the same rule applies: commercial insurance seldom reimburses off-label intravenous administration, though the associated psychiatric evaluation is sometimes billable and worth asking about specifically. The induction course is the part everyone discusses; what happens after it is the part that determines the real cost and the real commitment. Dosing for mood indications sits far below anaesthetic levels, typically calculated near 0.5 milligrams per kilogram of body weight and delivered slowly across about forty minutes. Read carefully, it says that what people looking at the United States providers usually want is the operational detail, and that is precisely what clinic marketing tends to omit.
Preparation shapes the experience more than most people expect. Clinics typically ask patients to avoid solid food for several hours beforehand, largely because of nausea, and to arrange a ride home, because driving is off the table for the remainder of the day. Beyond the logistics, the psychological preparation matters: going in with a settled expectation that the dissociative period is temporary, expected and monitored tends to make it far less alarming than encountering it cold. People who have discussed in advance what they will do if they feel frightened, and who know that the infusion can be slowed or stopped, generally describe a calmer experience than those who have not.
The underlying facts, stated once and clearly
That holds in the United States as it does everywhere: antagonism at the N-methyl-D-aspartate receptor appears to trigger a downstream cascade involving brain-derived neurotrophic factor and increased synaptic connectivity in mood-regulating regions. Where the evidence is strongest concerns short courses in adults who have not responded to at least two adequate antidepressant trials. In 2023 the FDA warned publicly about compounded ketamine used at home without monitoring, citing sedation, dissociation and airway risk with no clinician present. That is as true in the United States as anywhere else in the country. Appointment timing decides whether a course is compatible with employment, which is why the availability of early or late slots is more consequential than it sounds. It is worth carrying that into every conversation with a the United States provider. Dissociation is the effect people ask about most: a sense of distance from the body, altered time perception and sometimes visual distortion, typically peaking partway through and resolving within half an hour of the infusion ending.
Ketamine has been in continuous clinical use since the United States Food and Drug Administration approved it as a general anaesthetic in 1970, which makes it one of the better characterised drugs in modern medicine from a safety standpoint. What is new is not the molecule but the dose and the intention behind it. Anaesthetic dosing renders a person unconscious for surgery; the subanaesthetic dosing used in mood work is a fraction of that, typically calculated at around 0.5 milligrams per kilogram of body weight delivered slowly over roughly forty minutes. At that level the person stays awake, breathing on their own, able to speak and to signal discomfort. The half century of anaesthetic safety data is genuinely reassuring about the drug itself, and it is also not the same thing as long-term safety data for repeated low-dose psychiatric use, which is a younger and thinner body of evidence.
Making the decision with the information available
Cost is the constraint that settles the question for a large share of people, which makes the reluctance to publish prices worth noticing. It is the first thing to establish about any the United States programme. For anyone weighing options in the United States, ketamine work sits between psychiatric assessment and sedation management, and clinicians arrive at it from either side with correspondingly different instincts. Knowing in advance that the dissociative period is temporary, expected and monitored tends to make it considerably less frightening than encountering it unprepared. The population the trial evidence covers is narrower than the advertising implies, concentrating on adults who have not responded to at least two adequate antidepressant trials.
In 2023 the FDA issued a public warning about compounded ketamine products used at home without monitoring, citing risks including sedation, dissociation, airway compromise and the absence of any clinician present if something goes wrong. That warning is the clearest available signal about where the regulatory line sits. Telehealth has a legitimate and useful role in this field for consultation, screening, follow-up and integration therapy, and it materially improves access for people far from a metropolitan clinic. Using it to mail a dissociative anaesthetic to an unmonitored patient is a different proposition, and the distinction is worth insisting on.
Safety, screening and the limits of the evidence
The short version is that search results for ketamine treatment in the United States return a remarkably uniform set of pages, which makes genuine comparison harder rather than easier. The open question in the field is durability, which is why the maintenance conversation belongs in the first consultation rather than the seventh week. The subanaesthetic dose used in this work is a fraction of the surgical dose, which is why the person stays awake, breathing independently and able to communicate. Provider backgrounds in this field vary more than in almost any other corner of medicine, which is why credentials repay a closer reading than usual. Patients researching the United States providers run into this constantly. The headline per-session price usually excludes the consultation, any separately billed psychiatric evaluation, integration therapy and the maintenance sessions that follow.
Set aside the United States for a moment, because the general position comes first. Screening is where a careful programme distinguishes itself, and it happens before anyone discusses scheduling. A thorough intake covers cardiovascular history, because of the blood pressure response; personal and family history of psychosis or bipolar disorder, because of the risk of precipitating an episode; hepatic function, because the liver metabolises the drug; substance use history; current medications and their interactions; and pregnancy status. It should also establish what has already been tried and at what dose, since the term treatment-resistant carries a specific meaning that only applies after adequate trials of at least two antidepressants. A consultation that skips most of this and moves quickly to a package price is telling you something about how the clinic is run.
Why this question is harder than it should be
Anyone comparing the United States programmes will find this decisive: the mechanism matters practically because it implies the days after a session may be unusually receptive to therapeutic work. Applied to the United States, the point is this: travel time belongs in the treatment plan rather than being treated as a detail to solve later. Applied to the United States, the point is this: the infusion can be slowed or stopped if someone becomes distressed, and knowing that in advance is itself a meaningful part of preparation. The clinicians running these programmes come from anaesthesiology, psychiatry, emergency medicine and pain management, and the route shapes how the treatment is framed.
Every the United States programme is operating inside the same clinical framework, which runs as follows. A standard induction course in most American clinics runs to six sessions delivered over two to three weeks, though the number is a convention inherited from early trial protocols rather than a figure settled by comparative research. Some people are offered four; some programmes run to eight. What happens after induction is the genuinely unresolved part of the field. Response, where it occurs, is often not permanent, and many patients move onto a maintenance schedule of a single session every two to six weeks. Any clinic that presents six infusions as a complete and finished course without discussing what maintenance might look like, and what it might cost over a year, is describing half the treatment.
Putting this to use
Read against the the United States market, the phrase treatment-resistant carries a specific meaning, and it only applies after documented trials at appropriate doses and durations. For anyone weighing options in the United States, telehealth has a legitimate role here for consultation, screening, follow-up and integration therapy, and it materially improves access for people far from a metropolitan clinic. Weight-based dosing in the region of 0.5 milligrams per kilogram over roughly forty minutes is the convention, though clinics vary in whether they adjust it between sessions. The the United States listings on this page are organised so that this is checkable rather than assumed. In the United States the same rule applies: for anyone whose decision turns on cost, asking whether a provider offers esketamine as well as intravenous administration is among the higher-value questions available. Uncontrolled hypertension is treated as a serious caution for a straightforward physiological reason, and a programme that does not check blood pressure before dosing has skipped a step. Patients researching the United States providers run into this constantly.
Treatment decisions of this kind belong to a person and the clinician who knows their history. What a directory can usefully do is make sure nobody walks into that discussion missing something they needed.
This page is general information, not medical advice, and no directory can assess whether a treatment is appropriate for an individual. Ketamine is a controlled substance with genuine risks, and its use for mood disorders is off-label apart from esketamine, which holds FDA approval for treatment-resistant depression under a restricted programme. Decisions about treatment should be made with a qualified clinician who knows your full history. If you are in crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988 in the United States, or go to your nearest emergency department.